CIK 0001512762 · Accelerated filer<br>Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273615821
- Phone
- (650) 649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-11-17 | Lanfear Dennis M President & CEO | Gift | −10,000 | 436,684 | ||
| 2021-10-15 | Stilwell McDavid Chief Financial Officer | Sale | −3,507 | $16.80 | $59K | 31,611 |
| 2021-09-29 | HEALY JAMES Director | Sale | −286,076 | $16.12 | $4.6M | 0 |
| 2021-09-28 | HEALY JAMES Director | Sale | −48,329 | $17.17 | $830K | 286,076 |
| 2021-09-27 | HEALY JAMES Director | Sale | −100,150 | $18.06 | $1.8M | 334,405 |
| 2021-07-06 | Anicetti Vincent R Chief Operating Officer | Grant or award | +50,000 | 124,790 | ||
| 2021-07-06 | Anicetti Vincent R Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2021-06-09 | Stilwell McDavid Chief Financial Officer | Purchase | +3,700 | $13.42 | $50K | 35,118 |
| 2021-06-08 | Lanfear Dennis M President & CEO | Option exercise | +31,054 | $0.42 | $13K | 524,312 |
| 2021-06-08 | Lanfear Dennis M President & CEO | Sale | −31,054 | $13.56 | $421K | 493,258 |
| 2021-06-08 | Lanfear Dennis M President & CEO | Option exercise · Stock Option (Right to Buy) | −31,054 | 0 | ||
| 2021-06-06 | Lanfear Dennis M President & CEO | Option exercise | +300,000 | $0.42 | $125K | 493,258 |
| 2021-06-06 | Lanfear Dennis M President & CEO | Option exercise · Stock Option (Right to Buy) | −300,000 | 31,054 | ||
| 2021-05-21 | STOLPER MARK Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-05-21 | MENDELSON ALAN C Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2021-04-28 | Anicetti Vincent R Chief Operating Officer | Grant or award | +20,000 | 73,402 | ||
| 2021-04-28 | Stilwell McDavid Chief Financial Officer | Grant or award | +20,000 | 30,000 | ||
| 2021-04-28 | Stilwell McDavid Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2021-04-28 | Vexler Vladimir Chief Scientific Officer | Grant or award | +20,000 | 73,386 | ||
| 2021-03-09 | Vexler Vladimir Chief Scientific Officer | Option exercise | +24,356 | $2.08 | $51K | 89,502 |
Page 9 of 39 · 768 trades